CD274 and adenocarcinoma: In this study, the median PFS was 11 months and 9.3 months in patients with squamous cell carcinoma and adenocarcinoma who received paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor as first-line therapy, respectively.